Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Nagesh Kolishetti, Shanta Dhar, Pedro M. Valencia, Lucy Q. Lin, Rohit Karnik, Stephen J. Lippard, Robert Langer, Omid C. Farokhzad

Research output: Contribution to journalArticlepeer-review

482 Scopus citations


The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, wedescribe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we code-livered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH3)2(O2CCH2CH 2COOH)(OH)Cl2] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48-72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.

Original languageEnglish (US)
Pages (from-to)17939-17944
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number42
StatePublished - Oct 19 2010
Externally publishedYes


  • Chemotherapy
  • Drug delivery
  • Polymer-drug conjugate
  • Targeting
  • Temporal release

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy'. Together they form a unique fingerprint.

Cite this